Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bassetti, C; Beer, K; Beer, S; Buettner, U; Chofflon, M; Gass, A; Goebels, N; Gotschi-Fuchs, M; Kappos, L; Kesselring, J; Ludin, HP; Mattle, H; Schluep, M; Vaney, C; Baumhackl, U; Berger, T; Deisenhammer, F; Fazekas, F; Freimuller, M; Kollegger, H; Kristoferitsch, W; Lassmann, H; Markut, H; Strasser-Fuchs, S; Vass, K; Altenkirch, H; Bamborschke, S; Baum, K; Bayas, A; Benecke, R; Bruck, W; Buttmann, M; Chan, A; Daumer, M; Dommasch, D; Elias, WG; Fasshauer, E; Flachenecker, P; Gehlen, W; Gold, R; Haas, J; Haferkamp, G; Haller, P; Hartung, HP; Heesen, C; Heibel, M; Heidenreich, F; Hemmer, B; Henze, T; Hohlfeld, R; Janzen, RWC; Japp, G; Jung, S; Jugelt, E; Kallmann, B; Kieseier, BC; Kleinschnitz, C; Kohler, J; Kohler, W; Kolmel, W; Konig, N; Lehrieder, G; Leussink, V; Lowitzsch, K; Maurer, M; Manegold, U; Melms, A; Mertin, J; Neuhaus, O; Oschmann, P; Petereit, HF; Pette, M; Pohlau, D; Pohl, D; Rieckmann, P; Ruprecht, K; Sailer, M; Schipper, H; Schmidt, S; Schock, G; Schulz, M; Schwarz, S; Schwendemann, G; Seidel, D; Sommer, N; Stangel, M; Stark, E; Steinbrecher, A; Stoll, G; Toyka, KV; Tumani, H; Voltz, R; Wandinger, KP; Weber, F; Weilbach, F; Weinrich, W; Weissert, R; Wiendl, H; Wietholter, H; Wildemann, B; Zettl, UK; Ziemssen, T; Zipp, F; Zschenderlein, R; Rieckmann, P; Toyka, KV.
Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)
. 2006; 77(12): 1506-1518.
Doi: 10.1007/s00115-006-2220-x
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The updated recommendations presented here reflect new developments in the diagnostic work-up and immunotherapy of multiple sclerosis (MS) as well as optimization of medical care for MS patients. Monoclonal antibodies provide considerable improvement of treatment, but their use in basic therapy is restricted by their side effect profile. Thus, for the time being, natalizumab is only approved for monotherapy after basic treatment has failed or for rapidly progressive relapsing-remitting MS. In contrast, long-term data on recombinant beta-interferons and glatiramer acetate (Copaxone) show that even after several years no unexpected side effects occur and that a prolonged therapeutic effect can be assumed which correlates with the dose or frequency of treatment. Recently IFN-beta1b (Betaferon) was approved for prophylactic treatment after the first attack (clinically isolated syndrome, CIS). During treatment with beta-interferons, neutralizing antibodies can emerge with possible loss of effectivity. In contrast, antibodies play no role in treatment with glatiramer acetate. During or after therapy with mitoxantrone, serious side effects (cardiomyopathy, acute myeloid leukemia) appeared in 0.2-0.4% of cases. Plasmapheresis is limited to individual curative attempts in escalating therapy of a severe attack. According to the revised McDonald criteria, the diagnosis of MS can be made as early as the occurrence of the first attack (CIS). Recommendations for optimized care of MS patients are also new, thus implementing a resolution of the European Parliament.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - adverse effects
- Dose-Response Relationship, Drug - adverse effects
- Drug Administration Schedule - adverse effects
- Drug Approval - adverse effects
- Europe - adverse effects
- Evidence-Based Medicine - adverse effects
- Humans - adverse effects
- Immunologic Factors - adverse effects
- Interferon Type I, Recombinant - adverse effects
- Interferon-beta - adverse effects
- Mitoxantrone - adverse effects
- Multiple Sclerosis, Chronic Progressive - diagnosis
- Multiple Sclerosis, Relapsing-Remitting - diagnosis
- Neurologic Examination - drug effects
- Peptides - adverse effects
- Randomized Controlled Trials as Topic - adverse effects
- Registries - adverse effects
- Find related publications in this database (Keywords)
- multiple sclerosis
- immunomodulation
- monoclonal antibodies
- consensus